Puma Biotechnology: plasmaMATCH trial shows neratinib activity in ERBB2 cancer
Puma Biotechnology announced that its collaborators at The Institute of Cancer Research, London, presented results from the cohort of patients in the plasmaMATCH trial treated with Puma's drug neratinib at the 2019 San Antonio Breast Cancer Symposium in San Antonio, Texas. The oral presentation entitled, "Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer," and the poster presentation entitled, "Results from plasmaMATCH trial treatment Cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a ERBB2 mutation identified via ctDNA screening" were presented by Professor Nicholas Turner, M.D., Ph.D., Professor of Molecular Oncology at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, who is the principal investigator of the plasmaMATCH trial, and Andrew M. Wardley, M.D., consultant medical oncologist at The Christie NHS Foundation Trust in Manchester, England and Medical Director of the National Institute for Health Research Manchester Clinical Research Facility at The Christie, respectively. The plasmaMATCH trial was funded by Cancer Research UK. Approximately 1,044 patients with advanced breast cancer from approximately 20 sites in the United Kingdom registered for the trial and ctDNA results were available for 1,033 of the patients. The efficacy results from the trial showed that for the 20 efficacy evaluable patients, 5 patients experienced a confirmed objective response, and three further patients had unconfirmed responses. The median duration of response was 5.7 months, and the median progression free survival in this cohort of patients was 5.4 months.